The future of drug discovery is forged in yeast.
SKÍRNIR: a high-throughput synthetic biology platform designed to screen millions of protein pairs at biological speed.
Most serious diseases remain untreatable with conventional drugs.
Next-generation therapeutics offer new hope — but their discovery is slow, costly, and largely based on chance.
>80%
of disease-causing proteins remain undruggable
$12B
expected TPD drug market value within 10 years
5,000
protein pairs we can screen in a single week
Induced proximity and targeted protein degradation (TPD) — including molecular glues and PROTACs — are driving huge demand for platforms that can reveal the right protein pairs. While others chase the gold, we forge the tools and maps that make those breakthroughs possible.
SKÍRNIR Precision Screening
Our platform bypasses traditional computational simulation by utilizing live yeast cells as programmable screening vessels. We don't just predict protein interactions; we witness them at scale.
By leveraging high-throughput robotics and synthetic biology, Gleipnir Bioforge reduces the drug-discovery timeline from years to weeks, targeting previously 'undruggable' disease proteins.
Three properties that change drug discovery economics.
01
Faster
Weeks instead of months or years. SKÍRNIR collapses discovery cycles into a single working sprint.
02
Cost Effective
More validated hits for less spend. Yeast-based screening removes the cost floor of mammalian platforms.
03
Targeted
No needle-in-a-haystack. We surface the protein pairs most likely to disable your disease driver.
Accelerate your therapeutic pipeline.
We partner with global pharmaceutical leaders to solve the protein-targeting challenges of tomorrow.